Velusetrag
- Generic Name
- Velusetrag
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N4O5S
- CAS Number
- 866933-46-2
- Unique Ingredient Identifier
- J4VNV64ARB
- Background
Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders.
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
- Conditions
- Chronic Intestinal Pseudo-obstruction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 17
- Registration Number
- NCT05724069
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
🇮🇹Policlinico S.Orsola-Malpighi, Bologna, Italy
🇮🇹Aou Arcispedale Sant'Anna Di Cona, Cona, Italy
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 233
- Registration Number
- NCT02267525
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
- Conditions
- Gastroparesis
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 34
- Registration Number
- NCT01718938
- Locations
- 🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸GI Associates & Endoscopy Center, Jackson, Mississippi, United States
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT01467726
- Locations
- 🇺🇸
Comprehensive Clinical Development, Miramar, Florida, United States
Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)
- Conditions
- Chronic Constipation
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 360
- Registration Number
- NCT00391820
- Locations
- 🇺🇸
Breco Research, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.